Загрузка...

Budget 2026: Perspective on Healthcare and Biopharma Growth

Hitesh Sharma, Tax Partner, EY India highlights how Budget 2026 is a positive step for the healthcare and biopharma sector.

Key highlights include:
₹10,000 crore outlay to boost manufacturing for global purposes
Setting up 3 new institutes and upgrading 7 existing ones
Strengthening clinical trials, timelines, and protocols to meet global standards
Customs duty exemptions on drugs for cancer and rare diseases to improve affordability
Continued support for medical tourism, paramedical training, and mental health care

These measures signal the government’s commitment to building a stronger, more resilient healthcare ecosystem in India.

#UnionBudget2026 #Healthcare #Biopharma #EYIndia #MedicalInnovation #medicaltourism

Видео Budget 2026: Perspective on Healthcare and Biopharma Growth канала EY India
Яндекс.Метрика
Все заметки Новая заметка Страницу в заметки
Страницу в закладки Мои закладки
На информационно-развлекательном портале SALDA.WS применяются cookie-файлы. Нажимая кнопку Принять, вы подтверждаете свое согласие на их использование.
О CookiesНапомнить позжеПринять